Señales en vivo de XBIT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 16:00):

Stats
Volumen de hoy	92 519.00
Volumen promedio	75 375.00
Capitalización de mercado	233.56M
EPS	$-0.420 ( 2024-03-13 )
Próxima fecha de ganancias	( $0 ) 2024-05-08
Last Dividend	$2.50 ( 2021-07-15 )
Next Dividend	$0 ( N/A )
P/E	-9.47
ATR14	$0.0350 (0.46%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-03	Simard John	Buy	2 470 355	Convertible Loan Agreement
2023-06-23	Waldin Jan-paul	Buy	25 000	Director Stock Option
2023-06-23	Libby Peter	Buy	25 000	Director Stock Option
2023-06-23	Macadam Donald H.	Buy	25 000	Director Stock Option
2023-06-23	Mckenzie W Thorpe	Buy	25 000	Director Stock Option

INSIDER POWER
97.98
Last 100 transactions
Buy: 4 116 188 \| Sell: 11 979 897

Volumen Correlación

Largo: -0.22 (neutral)

Corto: -0.20 (neutral)

Signal:(43.011) Neutral

XBiotech Inc Correlación

10 Correlaciones Más Positivas
VVOS	0.88
BPRN	0.871
BELFA	0.856
CGO	0.845
CNTY	0.845
PASG	0.84
APLD	0.838
DORM	0.831
BBCP	0.815
ATNX	0.812

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

XBiotech Inc Correlación - Moneda/Commodity

-0.18
( neutral )

-0.28
( neutral )

0.00
( neutral )

-0.09
( neutral )

0.81
( strong )

-0.59
( weak negative )

XBiotech Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-1.74M (0.00 %)
EPS:	$-0.810

FY	2022
Ingresos:	$4.01M
Beneficio Bruto:	$3.36M (83.77 %)
EPS:	$-1.080

FY	2021
Ingresos:	$18.39M
Beneficio Bruto:	$12.57M (68.36 %)
EPS:	$-0.580

Financial Reports:

No articles found.

XBiotech Inc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

XBiotech Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$2.50	2021-07-15
Last Dividend	$2.50	2021-07-15
Next Dividend	$0	N/A
Payout Date	2021-07-23
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$2.50	--
Avg. Dividend % Per Year	1.55%	--
Score	0.63	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-05-01)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

0.63

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2021	$2.50	15.50%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-9.37	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.108	1.200	-3.60	-4.32	[0 - 0.3]
returnOnEquityTTM	-0.108	1.500	-2.31	-3.47	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	33.07	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	32.94	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	32.79	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.615	2.00	-0.205	-0.410	[0 - 30]
freeCashFlowPerShareTTM	-0.627	2.00	-0.314	-0.627	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.334	1.000	7.76	7.76	[0.2 - 0.8]
operatingProfitMarginTTM	-14.32	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0115	0.800	-3.26	-2.61	[0.5 - 2]
Total Score				-0.390

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.62	1.000	-1.073	0	[1 - 100]
returnOnEquityTTM	-0.108	2.50	-1.487	-3.47	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.627	2.00	-0.209	-0.627	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.615	2.00	-0.205	-0.410	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0806	1.500	-2.80	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-7.15	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-1.981

XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.